Search for Clinical Trial Results
Multiple Sclerosis, Chronic Progressive - 25 Studies Found
Status | Study |
Completed |
Study Name: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Condition:
Date: 2010-08-30 Interventions: Biological: MIS416 MIS416 intravenously every week |
Completed |
Study Name: Sunphenon in Progressive Forms of Multiple Sclerosis Condition: Multiple Sclerosis Date: 2008-11-28 Interventions:
|
Recruiting |
Study Name: A LOW-COST VIRTUAL REALITY GAMING PLATFORM FOR NEUROREHABILITATION OF HEMIPARESIS Condition:
Date: 2017-03-23 Interventions: Behavioral: Gaming CI Therapy Intensive remote (via video game) therapy for upper extremity hemiparesis. |
Recruiting |
Study Name: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Condition: Primary Progressive Multiple Sclerosis Date: 2016-11-08 Interventions:
|
Recruiting |
Study Name: Hydroxychloroquine in Primary Progressive Multiple Sclerosis Condition: Multiple Sclerosis, Primary Progressive Date: 2016-09-20 Interventions: Drug: Hydroxychloroquine Orally administered Hydroxychloroquine |
Available |
Study Name: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Condition: Multiple Sclerosis Date: 2016-06-16 Interventions: Drug: Ocrelizumab Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 d |
Recruiting |
Study Name: Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Condition:
Date: 2016-02-18 Interventions:
|
Completed |
Study Name: Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Condition: Multiple Sclerosis Date: 2016-01-14 Interventions: Drug: BG00012 (DMF) (Tecfidera®.) Subjects will take DMF 120 mg BID for the first 4 weeks of treatm |
Active, not recruiting |
Study Name: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo Condition: Primary Progressive Multiple Sclerosis Date: 2014-10-31 Interventions:
|
Active, not recruiting |
Study Name: Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Condition:
Date: 2014-10-03 Interventions:
|